IICT, Nosch Labs tie up for anti-Covid drug 2-DG
Nosch Labs will commence manufacture of 2-DG drug (2-Deoxy -D –Glucose) after obtaining regulatory clearances from the Drugs Controller General of India
Hyderabad: City-based Indian Institute of Chemical Technology (IICT) and Nosch Labs have entered into a non-exclusive agreement for the transfer of the process know-how for synthesis of anti-Covid drug 2-DG (2-Deoxy -D –Glucose).
Accordingly, Nosch Labs will commence manufacture of 2-DG drug after obtaining regulatory clearances from the Drugs Controller General of India (DCGI). The company intends to make the drug available at an affordable price, according to a release.
Dr Srivari Chandrasekhar, Director CSIR-IICT, said, “IICT has been instrumental in addressing numerous societal challenges and providing innovative solutions to Indian industries in the area of drugs and pharmaceuticals, agrochemicals, lipids, catalysis, functional materials, environmental, analytical, biological and engineering sciences. The institute has also undertaken clinical trials of various drugs repurposed to treat people infected with Covid.”
Hyderabad-based Nosch Labs has four manufacturing facilities in Telangana with an annual turnover of Rs 500 crore. The pharma company has international regulatory accreditation such as EU GMP, Korea GMP and Russian GMP certifications.
The company manufactures anti-ulcer, anti-fungal, anti-depressant, APIs, semi-finished and finished formulations and exports to more than 40 countries including Europe, South America, Russia, China and Korea.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
